{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:45:35Z","timestamp":1746107135856},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,18]]},"DOI":"10.1093\/ibd\/izy079","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T15:07:20Z","timestamp":1523632040000},"page":"1251-1265","source":"Crossref","is-referenced-by-count":5,"title":["Gene Signature\u2013Based Approach Identified MEK1\/2 as a Potential Target Associated With Relapse After Anti-TNF\u03b1 Treatment for Crohn\u2019s Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Kanae","family":"Gamo","sequence":"first","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuumi","family":"Okuzono","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yabuki","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ochi","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Sagara","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Pharmaceutical Technology Research and Development Laboratories, CMC Center, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Technology Research and Development Laboratories, CMC Center, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenyu","family":"Shiokawa","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Ebisuno","sequence":"additional","affiliation":[{"name":"Immunology Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"key\n\t\t\t\t20181009112307228_CIT0001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","article-title":"American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0002","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0003","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ajg.2011.448","article-title":"Has there been a change in the natural history of Crohn\u2019s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009","volume":"107","author":"Lakatos","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ibd.21118","article-title":"Small bowel resection rates in Crohn\u2019s disease and the indication for surgery over time: experience from a large tertiary care center","volume":"16","author":"Lazarev","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20181009112307228_CIT0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12703\/P7-44","article-title":"Pathogenesis of Crohn\u2019s disease","volume":"7","author":"Boyapati","year":"2015","journal-title":"F1000prime Rep"},{"key":"key\n\t\t\t\t20181009112307228_CIT0008","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"key\n\t\t\t\t20181009112307228_CIT0010","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/gutjnl-2011-300695","article-title":"Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease","volume":"61","author":"Kiesslich","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181009112307228_CIT0011","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial","volume":"116","author":"D\u2019haens","year":"1999","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1208\/s12248-012-9447-1","article-title":"Strategic applications of gene expression: from drug discovery\/development to bedside","volume":"15","author":"Bai","year":"2013","journal-title":"Aaps J"},{"key":"key\n\t\t\t\t20181009112307228_CIT0013","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cpt.318","article-title":"Leveraging big data to transform target selection and drug discovery","volume":"99","author":"Chen","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20181009112307228_CIT0014","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"key\n\t\t\t\t20181009112307228_CIT0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s13073-014-0095-1","article-title":"Systematic evaluation of connectivity map for disease indications","volume":"6","author":"Cheng","year":"2014","journal-title":"Genome Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0016","doi-asserted-by":"crossref","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181009112307228_CIT0017","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0016-5085(98)70476-7","article-title":"Early lesions of recurrent Crohn\u2019s disease caused by infusion of intestinal contents in excluded ileum","volume":"114","author":"D\u2019Haens","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0018","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181009112307228_CIT0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/nm.2470","article-title":"Isolation and in vitro expansion of human colonic stem cells","volume":"17","author":"Jung","year":"2011","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0021","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.stem.2011.02.020","article-title":"The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse","volume":"8","author":"Merlos-Su\u00e1rez","year":"2011","journal-title":"Cell Stem Cell"},{"key":"key\n\t\t\t\t20181009112307228_CIT0022","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.bmcl.2012.02.026","article-title":"Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy","volume":"22","author":"Adams","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20181009112307228_CIT0023","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejps.2010.10.003","article-title":"Engineering polymer blend microparticles: an investigation into the influence of polymer blend distribution and interaction","volume":"42","author":"Alhnan","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t20181009112307228_CIT0024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejps.2009.02.015","article-title":"Fabrication and in vivo evaluation of highly ph-responsive acrylic microparticles for targeted gastrointestinal delivery","volume":"37","author":"Kendall","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t20181009112307228_CIT0025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1126\/science.aaa0355","article-title":"Human genomics. The human transcriptome across tissues and individuals","volume":"348","author":"Mel\u00e9","year":"2015","journal-title":"Science"},{"key":"key\n\t\t\t\t20181009112307228_CIT0026","doi-asserted-by":"crossref","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"Dudley","year":"2011","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0027","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20181009112307228_CIT0028","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1091\/mbc.e07-04-0309","article-title":"Parallels between global transcriptional programs of polarizing caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer","volume":"18","author":"S\u00e4\u00e4f","year":"2007","journal-title":"Mol Biol Cell"},{"key":"key\n\t\t\t\t20181009112307228_CIT0029","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3655::AID-IMMU3655>3.0.CO;2-9","article-title":"Proliferation and apoptosis of lamina propria CD4+ T cells from scid mice with inflammatory bowel disease","volume":"28","author":"Bregenholt","year":"1998","journal-title":"Eur J Immunol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0031","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"key\n\t\t\t\t20181009112307228_CIT0032","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0016-5085(98)70420-2","article-title":"Clinical course of colorectal Crohn\u2019s disease: a 35-year follow-up study of 507 patients","volume":"114","author":"Lapidus","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0033","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.dld.2014.04.012","article-title":"Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn\u2019s disease: a retrospective study","volume":"46","author":"Chauvin","year":"2014","journal-title":"Dig Liver Dis"},{"key":"key\n\t\t\t\t20181009112307228_CIT0034","first-page":"24","article-title":"Intestinal epithelium in inflammatory bowel disease","volume":"1","author":"Coskun","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"key\n\t\t\t\t20181009112307228_CIT0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nri3608","article-title":"Intestinal epithelial cells: regulators of barrier function and immune homeostasis","volume":"14","author":"Peterson","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0036","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2013.00280","article-title":"Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics","volume":"4","author":"Pastorelli","year":"2013","journal-title":"Front Immunol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0037","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev-pathol-011811-120905","article-title":"The life and death of epithelia during inflammation: lessons learned from the gut","volume":"7","author":"Koch","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0038","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1111\/j.1572-0241.1999.01444.x","article-title":"Intestinal permeability test as a predictor of clinical course in Crohn\u2019s disease","volume":"94","author":"D\u2019Inc\u00e0","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0039","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/003655200750056637","article-title":"Abnormal intestinal permeability predicts relapse in inactive Crohn disease","volume":"35","author":"Arnott","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molmed.2011.05.011","article-title":"Enterocyte death and intestinal barrier maintenance in homeostasis and disease","volume":"17","author":"Vereecke","year":"2011","journal-title":"Trends Mol Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0041","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0042","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2012-303333","article-title":"Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations","volume":"62","author":"Planell","year":"2013","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181009112307228_CIT0043","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2008.02.030","article-title":"Altered enac expression leads to impaired sodium absorption in the noninflamed intestine in Crohn\u2019s disease","volume":"134","author":"Zeissig","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0044","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/0008-5472.CAN-13-3686","article-title":"B-raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells","volume":"75","author":"Herr","year":"2015","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20181009112307228_CIT0045","doi-asserted-by":"crossref","first-page":"G719","DOI":"10.1152\/ajpgi.00508.2010","article-title":"Constitutive activation of the MEK\/ERK pathway inhibits intestinal epithelial cell differentiation","volume":"301","author":"Lemieux","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0046","first-page":"B4820","article-title":"The role of CDX2 in inflammatory bowel disease","volume":"61","author":"Coskun","year":"2014","journal-title":"Dan Med J"},{"key":"key\n\t\t\t\t20181009112307228_CIT0047","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.devcel.2009.02.010","article-title":"Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2","volume":"16","author":"Gao","year":"2009","journal-title":"Dev Cell"},{"key":"key\n\t\t\t\t20181009112307228_CIT0048","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2015.12.042","article-title":"Organoid models of human gastrointestinal development and disease","volume":"150","author":"Dedhia","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112307228_CIT0049","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fphar.2016.00334","article-title":"Drug discovery via human-derived stem cell organoids","volume":"7","author":"Liu","year":"2016","journal-title":"Front Pharmacol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2015.01.160","article-title":"Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-\u03b1 production and endotoxin shock","volume":"458","author":"Du","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20181009112307228_CIT0051","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20181009112307228_CIT0052","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","article-title":"A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors","volume":"3","author":"Jahchan","year":"2013","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t20181009112307228_CIT0053","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1535-7163.MCT-13-0750","article-title":"Computational repositioning and preclinical validation of pentamidine for renal cell cancer","volume":"13","author":"Zerbini","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key\n\t\t\t\t20181009112307228_CIT0054","doi-asserted-by":"crossref","first-page":"e24662","DOI":"10.1371\/journal.pone.0024662","article-title":"Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer","volume":"6","author":"Claerhout","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181009112307228_CIT0055","volume-title":"Preparation of heterocyclic compounds as Raf inhibitors for treatment of cancer","author":"Hirose","year":"2009"},{"key":"key\n\t\t\t\t20181009112307228_CIT0056","volume-title":"Preparation of fused heterocyclic compounds as tyrosine kinase inhibitors","author":"Ishikawa","year":"2008"},{"key":"key\n\t\t\t\t20181009112307228_CIT0057","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1016\/j.bmc.2012.08.002","article-title":"Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2\/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy","volume":"20","author":"Kawakita","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"key\n\t\t\t\t20181009112307228_CIT0058","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.bmc.2012.07.032","article-title":"Design and synthesis of novel DFG-out RAF\/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives","volume":"20","author":"Hirose","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"key\n\t\t\t\t20181009112307228_CIT0059","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","article-title":"The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901","volume":"18","author":"Barrett","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20181009112307228_CIT0060","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20181009112307228_CIT0061","volume-title":"MEK1\/2 inhibitors, methods for their synthesis, and their use in disease treatment","author":"Dong","year":"2008"},{"key":"key\n\t\t\t\t20181009112307228_CIT0062","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1021\/jm2008634","article-title":"Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)\/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20181009112307228_CIT0063","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bmcl.2011.01.071","article-title":"Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer","volume":"21","author":"Dong","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20181009112307228_CIT0064","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.3.9.1313","article-title":"An evaluation of bicalutamide in the treatment of prostate cancer","volume":"3","author":"Schellhammer","year":"2002","journal-title":"Expert Opin Pharmacother"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/6\/1251\/25984030\/izy079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T16:01:25Z","timestamp":1571155285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/6\/1251\/4970154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,4,13]]},"published-print":{"date-parts":[[2018,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy079","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,4,13]]}}}